<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738621</url>
  </required_header>
  <id_info>
    <org_study_id>Scott and White</org_study_id>
    <nct_id>NCT00738621</nct_id>
  </id_info>
  <brief_title>Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients</brief_title>
  <official_title>A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott and White Hospital &amp; Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scott and White Hospital &amp; Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of the use of oral aprepitant in
      combination with intravenous ondansetron and dexamethasone with the efficacy provided by the
      use of oral aprepitant and dexamethasone for preventing vomiting during the first 24-48 hours
      after breast surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is one of the most common complications associated
      with surgery. The overall incidence of PONV is reported to be about 25-30% with specific
      surgeries having an incidence up to 70-80%.1-5 Although PONV is typically not life
      threatening, patients dread the sensation of nausea and the serious effects of retching and
      vomiting. PONV in the surgical patient can cause wound dehiscence, electrolyte imbalance,
      increased intraocular pressure, increased intracranial pressure, aspiration, esophageal
      rupture, and loss of vision due to retinal detachment. 6-11 In several studies, investigators
      found that patients rank vomiting as the most undesirable common side effect after surgery.
      PONV is costly in economic terms and is a reason day surgery patients must be admitted in the
      hospital for an overnight stay.12, 13 It is estimated that a patient who experiences an
      episode of vomiting costs an additional $300 based on emesis basins, supplies, gowns,
      bedding, additional medications, and nursing/physician time.14-20

      In general, PONV is highest in women (with a 2-3 times increased risk) and particularly after
      procedures such as gynecological surgery, laparoscopy, thyroidectomy and breast surgery.5,
      21-35 A study by Sinclair and group found that patients undergoing breast augmentation
      experienced an 8-10 fold higher incidence of PONV than patients undergoing other types of
      plastic surgery.26 Similar incidences were found in other studies of 48% to 68% of PONV in
      patients undergoing mastectomies, breast reconstruction, and implantation.36-40

      The hospitalization of patients undergoing breast cancer surgery has significantly decreased
      by 40% between 1993 and 2003. Many surgeries are now being performed on an outpatient basis
      according to the Agency for Healthcare Research and Quality (AHRQ), with 96% of lumpectomies,
      86% of partial mastectomies and 22% of complete mastectomies scheduled as ambulatory
      surgeries.41 Carroll and group found that 35% of outpatients suffered from nausea and
      vomiting after they left the surgical center.42 Therefore, the resulting problem is not only
      the high incidence of nausea and vomiting in this specific group of patients but the post
      discharge nausea and vomiting (PDNV) that will occur when these patients are at home and
      without direct medical oversight.

      Although still unclear, it is postulated that the etiology of postoperative nausea and
      vomiting is the central mechanism involving stimulation of the chemoreceptor trigger zone
      (CTZ) located bilaterally at the floor of the fourth ventricle in the area postrema. The CTZ
      is sensitive to toxins and other substances in the blood and cerebrospinal fluid. The CTZ
      also receives sensory signals from the gastro-intestinal tract. The are three major central
      nervous system (CNS) areas involved with PONV which all have specific emetogenic receptors.
      Blockade of these receptors is postulated to be the mechanism of action of the commonly used
      antiemetics. The agents' antagonist activity may be at one or more receptors with different
      binding affinities and acting at different emetic neuroreceptors. The multifactorial etiology
      of PONV involving multiple receptors is believed to be the reason one single agent is not
      100% effective. The administration of an agent working on one receptor type will typically
      reduce the PONV incidence by 30%. Use of a combination of antiemetic agents acting on
      different receptor sites will further reduce the incidence. This combination has shown
      greater efficacy than a single agent alone. Although this regimen has improved outcomes it
      has not eliminated the problem of PONV and patients needing rescue therapy post surgery
      occurs frequently. It would appear reasonable to assume that the use of more than 2
      antiemetics would further reduce the incidence of PONV.43 However; published evidence of
      greater than 2 agents is scarce. Therefore, the main objective of our proposal is to study a
      combination antiemetic regimen (3 agents vs. 2 agents) in females scheduled for breast
      surgery, a patient population considered at high risk for postoperative vomiting. The
      selected agents will cover different receptors based on the hypothesized PONV multifactorial
      etiology with stimulation of several factors. It is unknown which of these receptors may be
      stimulated and by which stimuli (anesthetic, surgery, or patient factors).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the efficacy of the use of oral aprepitant in combination with intravenous ondansetron and dexamethasone with the efficacy provided by the use of oral aprepitant in combination with dexamethasone alone for preventing vomiting for 1st 24hrs</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare efficacy of oral aprepitant in combination with IV ondansetron and dexamethasone with efficacy of dexamethasone and oral aprepitant alone for preventing vomiting during the 24-48 hours after breast surgery</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant, Dexamethasone, Ondansetron</intervention_name>
    <description>Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Emend=aprepitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant, Dexamethasone, Placebo</intervention_name>
    <description>Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time</description>
    <arm_group_label>A,2</arm_group_label>
    <other_name>Emend=aprepitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All of the following criteria must be met for the potential subject to be eligible for
        participation:

          1. The subject is a female scheduled to undergo ambulatory breast surgery performed under
             general anesthesia

          2. The subject is expected to undergo general inhalation anesthesia.

          3. The subject presents with two of the three following high-risk factors associated with
             PONV (must be in their medical history in order to be eligible)

               -  She is a non-smoker.

               -  She has documented history of PONV and/or motion sickness.

               -  She is expected to receive intra-operative and postoperative opioid.

          4. The subject's American Society of Anesthesiologist physical status is ASA I-III

          5. The subject is between18 to 65 years of age.

          6. The subject is expected to be discharged from the hospital/surgical center on the same
             day as the surgery.

          7. The subject has provided written informed consent to participate in the study.

        If any of the following exclusion criteria are met, the potential subject is NOT eligible
        for participation:

          1. The subject has a history of allergic reaction to, intolerances of or
             contraindications for any of the study medications or required anesthetic agents.

          2. The subject has received or is expected to receive any excluded preoperative drug
             within 48 hours prior to induction; or is expected to receive any excluded
             intra-operative or postoperative medications.

          3. The subject is pregnant or lactating. (If the potential subject is pre-menopausal, a
             urine pregnancy test must be performed within 24 hours/1 day of study prior to the
             planned surgery time and confirmed negative in order for the potential subject to be
             enrolled).

          4. The subject is taking warfarin.

          5. The subject has a history of alcohol and/or drug abuse within 1 year of study
             medication, or has a positive screening or pre-study test for alcohol or drugs of
             abuse.

          6. The subject is expected to require the use of a nasogastric tube postoperatively.

          7. The subject has a diagnosed latex allergy.

          8. The subject has used oral aprepitant (EmendÂ®) within the last 30 days.

          9. The subject has participated in a randomized study or has been exposed to any
             experimental drug within 30 days prior to enrollment of this study.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tricia A Meyer, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scott and White Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scott and White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Richard Beswick</name_title>
    <organization>Scott and White Healthcare</organization>
  </responsible_party>
  <keyword>PONV</keyword>
  <keyword>breast surgery</keyword>
  <keyword>prevention</keyword>
  <keyword>antiemetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

